ArticleMikrochimica acta2026
Electronic-conformational fusion hapten design boosts antibody sensitivity for chlorothalonil immunoassay.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chlorothalonil (CTN), a Group 2B probable carcinogen classified by the International Agency for Research on Cancer (IARC) and persistent broad-spectrum fungicide, requires ultrasensitive on-site monitoring. Conventional empirical hapten design for CTN immunoassays fundamentally limits antibody sensitivity, while the electronic-conformational fusion strategy presented significantly boosts detection sensitivity. A sensitive colloidal-gold immunochromatographic assay (CG-ICA) via this pipeline has been developed: four rationally designed haptens were screened in silico, with Hapten-1 (0.89 conformational similarity to CTN) identified as optimal. The derived monoclonal antibody 2C4 exhibited a half-maximal inhibitory concentration (IC₅₀) of 0.36 ng mL⁻¹ and < 0.01% cross-reactivity to 10 structural analogs in the buffer system, demonstrating excellent intrinsic binding performance and laying a solid foundation for subsequent on-site detection method development. AlphaFold3-based molecular docking first proposed a structurally plausible recognition model between CTN and the antibody. The established CG-ICA achieved a detection capability (CCβ) ≤ 120 ng g⁻¹ for the two tested vegetable matrices under the EU 2021/808 framework, which is compliant with the regulatory requirements of GB 2763 − 2021. The method showed 100% qualitative consistency with LC-MS/MS in the 20 tested real vegetable samples, supporting its reliability for on-site rapid screening. This workflow provides a quantitative design reference for hapten screening and antibody sensitivity improvement in small-molecule immunoassays.
Indexed as
Identifiers
42029792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.